1Perlow MJ, Freed WJ, Hoffer BJ, et al. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system[J]. Science, 1979,204(4393) : 643-647.
2Bjorklund A, Stenevi U. Reconstruction of the nigrostriatal pathway byintracerebral nigral transplants[J]. Brain Res, 1979,177(3) :555-560.
3Bjorklund A,Lindvall O.Cell replacement therapies for central nervous system disorders [ J ]. Nat Neurosci, 2000,3 (6) : 537-544.
4Piccini P, Brooks DJ, BjiJrklund A, et al. Dopamine release from nigral transplants visualized in vlvo in a Parkinson's patient I J]. Nat Neu rosci, 1999,2(12) : 1137-1140.
6Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease[ J]. N Engl J Med,2001,344(10) :710-719.
7Widner H, Tetrud J, Rehnerona S, et al. Bilateral fetal mesencephalic grafting in two patients with Parkinsonism induced by 1-methyl-4-phe-nyl-1,2,3,6-tetrahydropyridine(MPTP) [J]. N Engl J Med, 1992,327.(22):1556-1563.
8Spencer DD, Robbins RJ, Naftolin F, et al. Unilateral transplantation of human fetal mesencephallc tissue into the caudate nucleus of patients with Parkinson' s disease [ J ]. N Engl J Med, 1992,327 ( 22 ) : 1541-1548.
9Freed CR, Breeze RE, Rosenberg NL, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after trans-plantation for Parkinson's disease[J]. N Engl J Med, 1992,327(22) :1549-1555.
10Breeze RE, Wells TH Jr, Freed CR. Implantation of fetal tissue for the management of Parkinson's disease :a technical note[ J]. Neurosurgery,1995,36(5) :1044-1047.
